Christopher Albanese, Ph.D., announced as co-chair of Prevent Cancer Foundation’s Scientific Review Panel

للنشر الفوري

Audrey Kashatus
703-836-3687
audrey.kashatus@preventcancer.org

Alexandria, Va. – The Prevent Cancer Foundation^® today announced that Christopher Albanese, Ph.D., will serve as co-chair of its Scientific Review Panel after serving nearly two decades as a dedicated member. Dr. Albanese joins current co-chairs Electra D. Paskett, Ph.D. and James L. Mulshine, M.D.

The Foundation’s distinguished Scientific Review Panel is an independent, external group whose members review grant and fellowship applications for the Foundation. The group is also responsible for recommending awards for promising research with novel approaches for prevention and early detection. The Review Panel is comprised of members from renowned institutions such as the National Cancer Institute, MD Anderson Cancer Center, Johns Hopkins Cancer Center, the University of Pennsylvania and more.

Dr. Albanese is a Professor in the Departments of Oncology and Radiology at Georgetown University Medical Center and the Lombardi Comprehensive Cancer Center. Dr. Albanese is a member of the Cancer Cell Biology Program. In 2006, he founded the Preclinical Imaging Research Laboratory at the Lombardi Cancer Center and, in 2018, the Center for Translational Imaging. He continues to serve as the director of both. His work has resulted in over 195 peer-reviewed publications.

His research focuses on mutated versions of genes that can cause cancer and proteins that normally prevent or influence the development and growth of cancers in the urinary and reproductive systems, as well as other types of cancer. At the Lombardi Cancer Center, Dr. Albanese is working on programmatic development of novel preclinical models of human diseases and the development of high-energy imaging technologies.

Dr. Albanese received his doctorate in biology from Cardiff University in Wales, United Kingdom. Before joining the faculty at Georgetown University, Dr. Albanese worked at the Center for Cancer Research at Massachusetts Institute of Technology, Massachusetts General Hospital/Harvard Medical School, Northwestern University Medical School and the Albert Einstein College of Medicine in New York City.

He has also served as an associate editor of multiple renowned scientific journals, including The American Journal of Pathology, Journal of Neuroinfectious Diseases, Cell Cycle and has served as senior associate editor of Oncotarget/Pathology. Dr. Albanese has also been an ad hoc reviewer for journals including, but not limited to, Nature Medicine, Molecular Cell, Cancer Research and Molecular and Cellular Biology.

In addition to his work with the Foundation, Dr. Albanese has also served as the Chair of the NIH High End Equipment S10 Study Section, as an Integration Panel Member for the U.S. Department of Defense Prostate Cancer Research Program and worked with the Terry Fox Cancer Research Foundation.

“We are honored to welcome Dr. Albanese as co-chair of the Scientific Review Panel, where his expertise and commitment will help us continue identifying the brightest minds in our field,” said Jody Hoyos, CEO of the Prevent Cancer Foundation. “We look forward to his leadership that will support outstanding researchers whose innovative ideas can drive the next breakthroughs in cancer prevention and early detection.”

To learn about previously funded research projects driving key advancements in cancer prevention and early detection, explore the قاعدة بيانات جائزة مؤسسة الوقاية من السرطان.

###

حول مؤسسة الوقاية من السرطان^®

مؤسسة الوقاية من السرطان^® is the only U.S.-based nonprofit organization solely dedicated to cancer prevention and early detection. Through research, education, outreach and advocacy, we have helped countless people avoid a cancer diagnosis or detect their cancer early enough to be successfully treated. We are driven by a vision of a world where cancer is preventable, detectable and beatable for all.

تنهض المؤسسة لمواجهة التحدي المتمثل في تقليل وفيات السرطان بمقدار 40% بحلول عام 2035. ولتحقيق ذلك، نحن ملتزمون باستثمار $20 مليون في التقنيات المبتكرة للكشف عن السرطان مبكرًا وتعزيز فحص السرطان المتعدد، و$10 مليون لتوسيع نطاق فحص السرطان والتطعيم. الوصول إلى المجتمعات المحرومة طبيًا، و$10 مليون لتثقيف الجمهور حول خيارات الفحص والتطعيم.

For more information, please visit www.preventcancer.org.